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Available online 11 September 2016Background: Circulating microRNAs (miRNAs) emerge as potential heart failure biomarkers. We aimed to identify
associations between acute heart failure (AHF)-specific circulating miRNAs and well-known heart failure
biomarkers.
Methods: Associations between 16 biomarkers predictive for 180 day mortality and the levels of 12 AHF-specific
miRNAs were determined in 100 hospitalized AHF patients, at baseline and 48 hours. Patients were divided in 4
pre-defined groups, based on clinical parameters during hospitalization. Correlation analyses between miRNAs
and biomarkers were performed and complemented by miRNA target prediction and pathway analysis.
Results: No significant correlations were found at hospital admission. However, after 48 hours, 7 miRNAs were
significantly negatively correlated to biomarkers indicative for a worse clinical outcome in the patient group with
the most unfavorable in-hospital course (n = 21); miR-16-5p was correlated to C-reactive protein (R =−0.66,
p-value=0.0027),miR-106a-5p to creatinine (R=−0.68, p-value=0.002),miR-223-3p to growthdifferentiation
factor 15 (R=−0.69, p-value= 0.0015), miR-652-3p to soluble ST-2 (R=−0.77, p-value b 0.001), miR-199a-3p
to procalcitonin (R =−0.72, p-value b 0.001) and galectin-3 (R =−0.73, p-value b 0.001) and miR-18a-5p to
procalcitonin (R =−0.68, p-value = 0.002). MiRNA target prediction and pathway analysis identified several
pathways related to cardiac diseases, which could be linked to some of the miRNA-biomarker correlations.
Conclusions: The majority of correlations between circulating AHF-specific miRNAs were related to biomarkers
predictive for a worse clinical outcome in a subgroup of worsening heart failure patients at 48 hours of hospitaliza-
tion. The selective findings suggest a time-dependent effect of circulatingmiRNAs and highlight the susceptibility to
individual patient characteristics influencing potential relations between miRNAs and biomarkers.
© 2016 Published by Elsevier Ireland Ltd.Keywords:
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Since the discovery ofmicroRNAs (miRNAs)more than twenty years
ago [1,2], the knowledge about their role in several disease processes
has increased substantially. MiRNAs are small RNA particles (~22
nucleotides in length) with the ability to regulate gene expression at
the post-transcriptional level [3,4]. This processmainly involves binding
to complementary sequences of the messenger RNA (mRNA) after
which it leads to translational repression or degradation of the mRNA
[5]. MiRNAs are thought to play a role in a variety of pathophysiological
mechanisms, including the development of heart failure [6].
Extracellular miRNAs are measurable in the circulation and are in-
creasingly reported as potential diagnostic and prognostic biomarkers
for multiple diseases [7]. Furthermore, owing to their stability, circulat-
ing miRNAs may be attractive new biomarkers in the cardiovascular
field [8,9]. Recently, our group reported about a panel of 12 circulating
miRNAs specifically associated with acute heart failure (AHF) [10].
These miRNA levels were found to be lower in patients with AHF com-
pared to chronic heart failure patients, patients with an acute exacerba-
tion of chronic obstructive pulmonary disease, and healthy controls.
Further decreasing levels after 48 h of hospitalization in a subset of
these miRNAs were predictive for 180 day mortality in patients with
AHF. However, the meaning and role of these circulating miRNA levels
in patients with AHF remain to be established.
Several other, protein based biomarkers in heart failure have been as-
sociatedwithdifferent cardiac disease pathways such as angiogenesis, en-
dothelial function, inflammation, cardiac stretch and remodeling, as well
as to clinical outcome [11–13]. Early in-hospitalworsening of heart failure
is an important determinant for a worse prognosis [14–16]. We hypothe-
size that changes in AHF-specific miRNAs and other, protein based bio-
markers between baseline and 48 h may indicate their role in heart
failure related disease processes contributing to end organ damage and
hence to a worse outcome. Therefore, by comparing the levels of bio-
markerswithmiRNAs related to AHF,we aim to increase our understand-
ing of the role and potential function of these specific miRNAs in the
circulation. In the present studywe study associations early during hospi-
talization between AHF-related circulating miRNAs and other novel and
established biomarkers. We additionally use a bioinformatic approach to
identify putativemiRNA targets and enrichedpathways to gain further in-
sight into potentially related pathways and mechanisms.
2. Methods
2.1. Study population
A subset of 100 patients hospitalized for AHF from the Placebo-
Controlled Randomized Study of the Selective A1 Adenosine Receptor
Antagonist Rolofylline for Patients HospitalizedWith Acute Decompen-
sated Heart Failure and Volume Overload to Assess Treatment Effect on
Congestion and Renal Function (PROTECT) was studied. The PROTECT
study design and results have been described elsewhere [17,18]. The
24 healthy control subjects were derived from the Telosophy study, as
previously reported [10,19]. The PROTECT and Telosophy study proto-
cols conform to the ethical guidelines of the 1975 Declaration of Helsin-
ki as reflected in a priori approval of the ethics committees of the
participating centers. All patients gave informed consent.
2.2. Blood sample collection
Blood sampleswere collected at various time points during hospital-
ization, including baseline and 48 h. Plasma was collected from EDTA
blood as reported before [17]. Briefly, plasma sampleswere shipped fro-
zen to the central laboratory where central study measurements were
performed. Samples were then stored in−70 °C/−80 °C freezers and
sent frozen to our center. Here, the samples were aliquoted and again
stored in−80 °C freezers.2.3. Biomarker measurements
Laboratory values including albumin, alanine transaminase, aspar-
tate transaminase, bicarbonate, blood urea nitrogren (BUN), chloride,
creatinine, glucose, hemoglobin, platelet count, potassium, red blood
cell count, sodium, total cholesterol, triglycerides, uric acid and white
blood cell count were measured in a central laboratory (ICON Laborato-
ries, Farmingdale, NY, USA). Frozen aliquots were sent to Alere™, (San
Diego, CA), which were used for the protein based biomarker measure-
ments. The biomarkers galectin-3, myeloperoxidase and neutrophil
gelatinase-associated lipocalin were determined by means of sandwich
enzyme-linked immonsorbent assays (ELISA) on a microtiter plate.
Angiogenin and C-reactive protein (CRP)weremeasured using compet-
itive ELISAs on a Luminex® platform. Sandwich ELISAs on a Luminex®
platform were used for measuring D-dimer, endothelial cell-selective
adhesion molecule, growth differentiation factor 15 (GDF-15),
lymphotoxin beta receptor, mesothelin, neuropilin, N-terminal pro C-
type natriuretic peptide, osteopontin, procalcitonin (PCT), pentraxin-3,
periostin, polymeric immunoglobulin receptor, pro-adrenomedullin
(proADM), prosaposin B, receptor for advanced glycation endproducts,
soluble ST-2 (sST-2), syndecan-1, tumor necrosis factor alpha receptor
1 (TNFR-1), tumor necrosis factor receptor superfamilymember, vascu-
lar endothelial growth receptor 1 (VEGFR-1) and WAP four-disulfide
core domain protein HE4 (WAP-4C). The immunoassays for PCT,
proADM, galectin-3 and ST2, developed by Alere, have not been stan-
dardized to the commercialized assays used in research or in clinical
use and the extent to which each Alere assay correlates with the com-
mercial assay is not fully characterized. Details about the biomarker as-
says including cut-off values, detection limits and inter assay
coefficients of variation were published elsewhere [20].
2.4. Quantitative reverse transcription-polymerase chain reaction (qRT-
PCR)
MiRNA isolation and profilingwere conducted in the same laborato-
ry with standard procedures and commercial kits and assays as detailed
in the recent paper of Ovchinnikova et al. [10] and the Supplementary
Material. Once the samples were thawed, the miRNA isolation and
PCRs were directly performed, avoiding additional freeze/thaw cycles.
The miRCURY RNA isolation kit for bodyfluids (Exiqon, Vedbaek,
Denmark) was used to isolate RNA from 200 μl of plasma. Using the
Exiqon Serum/Plasma Focus microRNA PCR panel, the expression of
375 miRNAs was measured in 10 AHF patients. Fifteen miRNAs which
exhibited a statistically significant difference (with a Bonferroni
corrected p-value threshold of ≤0.00022) and a 4-fold change in the
AHF samples compared to the control samples were selected and ana-
lyzed in an extended cohort of 100 AHF patients. For this, a customized
panel containing the 15 miRNAs of interest was used (Exiqon). The ref-
erence genesmiR-30a-5p andmiR-194-5pwere selected and remained
constant in the patient and control samples. Expression levels were nor-
malized against these reference genes and the comparative delta–delta-
CT method was used to calculate relative expression levels (GenEx Pro-
fessional software, MultiD Analyses, Sweden). Out of these 15 miRNAs,
12 miRNAs (let-7i-5p, miR-16-5p, miR-18a-5p, miR-26b-5p, miR-27a-
3p, miR-30e-5p, miR-106a-5p, miR-199a-3p, miR-223-3p, miR-423-
3p, miR-423-5p and miR-652-3p) were validated in an independent
AHF cohort and were used for the analyses in this study [10].
2.5. Statistical analyses
MiRNA expression data was handled using GenEx Professional soft-
ware, MultiD Analyses, Sweden. All other statistical analyses were con-
ducted using R: A Language and Environment for Statistical Computing,
version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria).
Receiver operating characteristic (ROC) analyseswere performed to ob-
tain the area under the ROC curve, using the R package pROC.
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formed to determine the predictive value of the biomarkers for
180 day mortality, including Harrell's C-index calculation. Correlation
analyses were performed using the Spearman Rank test from the R
package Hmisc. Hierarchical clustering of correlation coefficients and il-
lustrating them in heatmaps were performed using the R package
gplots. Principle component analysis (PCA) was conducted for the
miRNAs and biomarkers in all clinical groups at baseline and 48 h
using the R packages devtools and ggbiplot. The purpose of thismethod,
as previously used by others [21], was to correct for multiple testing in
our correlation analyses based on the number of components
explaining 95% of the variance of themiRNAs and biomarkers in all clin-
ical groups at baseline and 48 h, leading to a corrected p-value threshold
of 0.002941 for baseline and 0.002778 for 48 h (Supplementary
Table 1). P-values of b0.05 were deemed statistically significant for all
other analyses. Target prediction of the miRNAs was performed by
means of the DNA Intelligent Analysis (DIANA)-micro T-CDS (v.5.0)
prediction algorithm [22] after which pathway analysis was conducted
with DIANA-miRPath (v.2.0) [23]. The micro T-CDS threshold score for
predicted targets was set at 0.8 and the p-value threshold at p b 0.05.
Correcting for multiple testing was taken into account using False Dis-
covery Rate (FDR) correction.
3. Results
3.1. Diagnostic accuracy of the selected miRNAs
In a previous publication of our groupwe identified a set of circulat-
ing miRNAs associated with AHF [10]. To confirm the discriminating
properties of the selectedmiRNAs between the investigated AHF cohort
and a group of 24 previously described healthy control patients [10], we
performed ROC analyses. All 12 miRNAs showed high area under the
ROC curve (AUC) values within a range of 0.82–0.97 (as presented in
Supplementary Table 2).
3.2. Selection of biomarkers
We selected from the total PROTECT dataset (n=2033) 16 out of 43
established and novel biomarkers significantly predictive for 180 day
all-cause mortality at 48 h with a C-index of ≥0.60 (Table 1). In theTable 1
Cox proportional hazard regression analysis for 180 day all-cause mortality.
Biomarker Hazard ratio (95% CI) P-value C-index
BUN 1.8 (1.6–2.0) b0.001 0.67
sST-2 1.7 (1.5–1.9) b0.001 0.65
WAP-4C 1.6 (1.4–1.9) b0.001 0.63
VEGFR-1 1.5 (1.4–1.7) b0.001 0.63
Total cholesterol 0.6 (0.5–0.7) b0.001 0.63
CRP 1.5 (1.4–1.8) b0.001 0.62
ProADM 1.7 (1.4–1.9) b0.001 0.62
Procalcitonin 1.5 (1.3–1.6) b0.001 0.62
Galectin-3 1.5 (1.3–1.7) b0.001 0.61
TNFR-1 1.5 (1.3–1.6) b0.001 0.61
Albumin 0.7 (0.6–0.8) b0.001 0.61
Syndecan-1 1.4 (1.2–1.6) b0.001 0.60
GDF-15 1.5 (1.3–1.7) b0.001 0.60
Sodium 0.7 (0.7–0.8) b0.001 0.60
Triglycerides 0.7 (0.6–0.8) b0.001 0.60
Creatinine 1.4 (1.3–1.6) b0.001 0.60
Univariable Cox regression analysis at 48 h of hospitalization. Biomarkers with a C-index
of ≥0.60 are depicted with the Hazard Ratio (95% CI) and p-value. Hazard ratio should
be interpreted per standard deviation. All biomarkers except for albumin, proADM, sodi-
um and total cholesterol were log-transformed. Performance of the model was calculated
with the concordance index (C-index). BUN indicates blood urea nitrogen; sST-2, soluble
ST-2;WAP-4C,WAP four-disulfide core domain protein HE4; VEGFR-1, vascular endothe-
lial growth factor receptor 1; CRP, C-reactive protein; proADM, pro-adrenomedullin;
TNFR-1, tumor necrosis factor alpha receptor 1 and GDF-15, growth differentiation
factor 15.majority of cases, higher levels of biomarkers were indicative for a
worse clinical outcome. However, for albumin, total cholesterol, sodium
and triglycerides, lower levels were predictive for 180 day all-cause
mortality.
3.3. Selection of patient groups
The subpopulation of 100 AHF patients was comparable to the total
PROTECT population (Supplementary Table 3). Patients were divided
into 4 groups based on clinical characteristics and the trichotomous
endpoint of the PROTECT study [18] (Treatment Failure, Success and
Unchanged), which reflects the in-hospital clinical course of the pa-
tients. To further distinguish the patients with the worst in-hospital
course in the Failure group, additional criteria divided the Failure pa-
tients in failure-intermediate and failure-worsening patients. The group
criteria have been schematically depicted in Fig. 1. The baseline charac-
teristics (Table 2) show that groups did not significantly differ except for
a worse renal function and higher numbers of prior beta-blocker use in
the failure groups and small differences in the New York Heart Associa-
tion (NYHA) classification. In contrast, the clinical in-hospital character-
istics and outcome parameters show a clear shift from patients in the
improving and no change groups to patients belonging to the failure
groups and especially the worsening group, with higher mortality rates
in the failure groups.
3.4. Correlation between miRNAs and biomarkers
Correlation analyses were performed for the 12 miRNAs and 16 se-
lected biomarkers at baseline and 48 h. The p-value threshold to reach
significance was adjusted to correct for multiple testing by dividing
0,05 by the components which explained 95% of the variance per time
point, resulting from thePCA. For baseline, a total of 17principal compo-
nents explained 95% of the cumulative proportion of variance and con-
sequently, the adjusted p-value threshold was set as 0.05/17 =
0.002941. For 48 h, a total of 18 principal components resulted in an ad-
justed p-value threshold of 0.05/18 = 0.002778 (Supplementary
Table 1). At baseline level, no significant correlations were found be-
tween the circulating miRNAs and biomarkers. Correlation analyses at
48 h of hospitalization showed a clear gradual trend of more negative
correlations from the improving group to the failure-worsening group
(Fig. 2). Overall, 9 significant negative correlations were detected. One
significant negative correlation in the improving group between miR-
30e-5p and VEGFR-1 (R = −0.59, p-value = 0.002) and 1 between
let-7i-5p and triglycerides (R = −0.51, p-value = 0.0027) in the
failure-intermediate group. Seven out of 9 significant negative correla-
tions were observed in the failure-worsening group between miR-16-
5p and CRP (R =−0.66, p-value = 0.0027), miR-106a-5p and creati-
nine (R = −0.68, p-value = 0.002), miR-223-3p and GDF-15
(R =−0.69, p-value = 0.0015), miR-652-3p and sST-2 (R =−0.77,
p-value b 0.001), miR-199a-3p and PCT (R =−0.72, p-value b 0.001),
miR-18a-5p and PCT (R =−0.68, p-value = 0.002) and miR-199a-3p
and galectin-3 (R = −0.73, p-value b 0.001). A complete list of all
correlation results are depicted in Supplementary Table 4.
3.5. In silico miRNA target prediction and pathway enrichment analysis
Computational bioinformatic tools were used to identify putative
miRNA targets. Targetswere predicted bymeans of DIANA-micro T-CDS
(v.5.0). Of these predicted targets, 4 target genes were identified
encoding for 4 of our selected biomarkers. MiR-30e-5p and miR-106-
5p were found to target FLT1, encoding for VEGFR-1 (predicted by
DIANA microT-CDS, TargetScan and MiRanda), miR-199a-3p targets
IL1RL1, encoding for sST-2 (predicted by DIANA microT-CDS and
MiRanda) and miR-27a-3p has ALB as putative target, encoding for
albumin (predicted by DIANAmicroT-CDS andMiRanda). Interestingly,
miR-30e-5p and VEFGR-1 were also significantly negatively correlated
Failure
• Death or HF re-admission to day 7 
• Worsening HF symptoms from >1 
to 7 days after treatment, requiring 
rescue therapy 
• Persistent renal impairment 
No change 
(n=16)
Neither treatment success nor 
treatment failure 
Improving
(n=25)
• Improvement in dyspnea 
(7-point Likert scale) 
• Not a treatment failure  
Failure-worsening  
(n=21) 
Failure criteria + additionally the 
following: 
• Dyspnea moderately or markedly 
worse (24-48h) on the Likert scale 
OR
• Rescue therapy with inotropes OR 
mechanical ventilation (during 
hospitalization/until day 7) 
Failure-intermediate 
(n=38) 
Only failure criteria 
Fig. 1. Patient grouping according to PROTECT primary endpoint definitions. Patients (n = 100) were divided in 4 groups based on the trichotomous endpoint of the PROTECT study;
Treatment Failure, Unchanged (=no change) or Success (=improving). The patients in the Failure group were further divided in failure-worsening and failure-intermediate based on
additional clinical criteria for the failure-worsening group.
234 E.L. Vegter et al. / International Journal of Cardiology 224 (2016) 231–239in our dataset in the improving group (Fig. 2). Pathway analysis on the
predicted targets using DIANA-miRPath (v.2.0) led to the identification
of 47 significant KEGG pathways in which the predicted miRNA
targetswere enriched (Fig. 3, Supplementary Table 5).MultiplemiRNAs
and corresponding predicted target genes were involved in top-
enriched pathways which have previously been implicated in cardiac
disease and heart failure, including the PI3K-Akt signaling pathway
(p = 1.80e−12), ErB signaling pathway (p = 6.22e−12), transforming
growth factor–beta (TGF-β) signaling pathway (p = 6.87e−11) and
ubiquitin mediated proteolysis (p = 1.45e−10). In a set of 4274 cardio-
vascular related genes extracted from the Cardiovascular Gene Ontolo-
gy Annotation list (http://www.ebi.ac.uk/QuickGO/GProteinSet?id=
BHF-UCL), 1178 (23%) of the AHF-associated miRNA targets, as
predicted by DIANA-micro-T-CDS, overlapped with the cardiovascular
related genes.
4. Discussion
Increasing interest in circulating miRNAs has led to several
questions regarding their role in the circulation, origin and reflection
of various disease processes. With the present study, we aimed to
gain insight in the role and potential function of circulating miRNAs
in AHF patients with the help of other well-known circulating bio-
markers. First, we showed that correlations between biomarkers
and miRNAs not only depend on the time of measurement, but on
the disease state of the patient as well. Specifically in those patients
with the worst clinical course during hospitalization, which were
characterized by a worsening renal function, the need of rescue ther-
apy, worsening dyspnea symptoms at 24 to 48 h and a poor outcome,
we found several significant negative correlations. The negative
correlations reflect an inverse relationship in which biomarker levels
increase and miRNA levels decrease and vice versa. These results are
in line with the previously found association of this panel of decreas-
ing miRNAs with the most acute state of heart failure [10], which are
strengthened by this corresponding biomarker profile. In contrast,
no significant correlations were found at time of admission and
only 1 in both the failure-intermediate and improving group at 48 h
of hospitalization, suggesting that variation in clinical characteris-
tics, medication use and the time point of measurement during
hospitalization may be of great influence. This may be valuableinformation for future research regarding circulating miRNAs and
biomarkers and brings additional challenges to light.
Six of the 7 biomarkers with significant correlations with 7 of the
AHF-associated miRNAs are known to play a role in important cardiac
disease processes such as inflammation, cardiac remodeling/fibrosis
and angiogenesis [24]. GDF-15 and CRP are inflammatory markers and
also the level of PCT rises in response to pro-inflammatory stimuli [25,
26]. Increased levels of sST-2, a novel biomarker of cardiac stress, reflect
the severity of adverse cardiac remodeling and tissue fibrosis in re-
sponse tomyocardial infarction, acute coronary syndromeorworsening
heart failure [27]. Galectin-3 is involved inmultiple biological processes
and has been shown to play a role in inflammation, fibrosis and heart
failure [28–30].
The correlation identified in the failure-worsening group between
CRP and miR-16-5p is supported by the study of Castro-Villegas et al.
[31] MiR-16-5p was found to be significantly upregulated following
therapy with anti-TNFα/disease-modifying anti-rheumatic drugs in pa-
tients with rheumatoid arthritis. Only responder patients showed an in-
crease in miR-16-5p and 5 other miRNAs after therapy which was
paralleled by the reduction of CRP. Therefore, as this previous study
and our data demonstrate, miR-16-5p might be co-regulated with the
inflammation factor CRP.
Another observed correlation between galectin-3 and miR-199a-3p
in the failure-worsening group might be explained by the relevance of
cardiac remodeling and fibrosis in heart failure. Galectin-3 expression
is increased in cases of liver-, renal- and cardiac fibrosis as well as idio-
pathic pulmonary fibrosis [29,32–34]. MiR-199a was also associated
with heart failure [35] and fibrotic processes in the lung and liver
[36–38]. In a recent study of Yang et al. miR-199a-5p was significantly
increased in serums of idiopathic pulmonary fibrosis patients [39].
These results suggest a potential interaction between miR-199a and
fibrotic processes which might also be important in heart failure.
Furthermore, miR-652-3p was found to be correlated with sST-2 in
the failure-worsening group. Decreased serum levels of miR-652 in pa-
tients with chronic liver disease suggest a putative role of this miRNA
in the mediation of fibrogenic and inflammatory processes which may
explain the observed correlationwith sST-2, a marker of fibrosis and in-
flammation elevated in patients under cardiac stress [40]. Interestingly,
low levels of circulating miR-652-3p were predictive for a heart failure
admission within 5 years in post-acute coronary syndrome patients
Table 2
Baseline- and outcome characteristics of the 4 AHF patient groups.
Characteristics Failure No change Improving
Worsening (n = 21) Intermediate (n = 38) (n = 16) (n = 25) P-trend
Demographics
Sex, % male (n) 57.1 (12) 42.1 (16) 75 (12) 40 (10) 0.644
Age (years) 63.1 ± 12.2 73.5 ± 9.2 67.1 ± 11.8 68 ± 11.4 0.413
Systolic Blood Pressure (mmHg) 110.3 ± 13.8 123.4 ± 18.4 120.3 ± 14.4 120.5 ± 17.4 0.082
Diastolic Blood Pressure (mmHg) 66.8 ± 10.7 72.1 ± 11 72.5 ± 10.9 73 ± 13.8 0.082
Heart Rate (beats/min) 75.3 ± 8.8 79.7 ± 16.3 74.8 ± 17 82.4 ± 17.8 0.262
Rolofylline Administration, % (n) 52.4 (11) 68.4 (26) 62.5 (10) 64 (16) 0.611
Clinical profile
Orthopnea, % (n) 95.2 (20) 94.7 (36) 87.5 (14) 100 (25) 0.596
Rales, % (n) 38.1 (8) 57.9 (22) 75 (12) 60 (15) 0.119
Edema, % (n) 76.2 (16) 71.1 (27) 62.5 (10) 60 (15) 0.190
Creatinine (mg/dL) 2 [1.6–2.2] 1.4 [1.2–1.9] 1.3 [1.2–1.7] 1.2 [1.1–1.4] b0.001
Creatinine Clearance (ml/min) 33.4 [25.9–40.1] 42.2 [35.1–57.5] 53.4 [38.9–64.4] 57.8 [44.6–66.7] b0.001
Blood Urea Nitrogen (mg/dL) 50 [36–83] 30 [26–45.8] 28.5 [24.8–40] 25 [22–32] b0.001
Medical history, % (n)
Heart failure 100 (21) 94.7 (36) 93.8 (15) 96 (24) 0.571
Hypertension 76.2 (16) 84.2 (32) 75 (12) 92 (23) 0.252
Diabetes Mellitus 42.9 (9) 55.3 (21) 31.2 (5) 36 (9) 0.280
Hypercholesterolemia 61.9 (13) 47.4 (18) 37.5 (6) 44 (11) 0.221
Ischemic Heart Disease 76.2 (16) 73 (27) 81.2 (13) 68 (17) 0.646
Atrial Fibrillation 61.9 (13) 63.2 (24) 50 (8) 52 (13) 0.339
Stroke 14.3 (3) 10.5 (4) 6.2 (1) 4 (1) 0.190
COPD 19 (4) 21.1 (8) 6.2 (1) 8 (2) 0.136
NYHA Class 0.021
2 19 (4) 13.2 (5) 12.5 (2) 16 (4)
3 52.4 (11) 52.6 (20) 50 (8) 60 (15)
4 28.6 (6) 28.9 (11) 31.2 (5) 20 (5)
Hospitalized for heart failure in the past year 76.2 (16) 68.4 (26) 62.5 (10) 56 (14) 0.132
Prior medication use, % (n)
ACE inhibitors or ARB 57.1 (12) 68.4 (26) 68.8 (11) 76 (19) 0.204
Beta Blockers 90.5 (19) 78.9 (30) 75 (12) 64 (16) 0.034
Mineralocorticoid Receptor Antagonists 61.9 (13) 50 (19) 56.2 (9) 36 (9) 0.116
Clinical outcomes
Diuretic Responsea (kg) −0.1 ± 0.4 −0.3 ± 0.4 −0.4 ± 0.5 −0.6 ± 0.8 0.004
Weight change baseline - day 4 (kg) −0.3 ± 3.7 −2.3 ± 2.7 −2.5 ± 2.3 −3.3 ± 3.3 0.005
Total diuretic dose, baseline - 48 h (mg) 680 [249–960] 309.9 [152.5–532.5] 240 [152.5–305] 235.6 [160–280] b0.001
Inotropics, % (n) 85.7 (18) 0 (0) 0 (0) 0 (0) b0.001
Moderately or marked worsening of dyspnea at 24 h and/or 48 h, % (n) 28.6 (6) 0 (0) 0 (0) 0 (0) 0.001
Mechanical Ventilation, % (n) 9.5 (2) 0 (0) 0 (0) 0 (0) 0.055
WRF, day 7, % (n) 38.1 (8) 42.1 (16) 0 (0) 12 (3) 0.003
Treatment failure due to death, % (n) 4.8 (1) 0 (0) 0 (0) 0 (0) 0.177
Treatment failure due to Worsening Heart Failure, % (n) 95.2 (20) 78.9 (30) 0 (0) 0 (0) b0.001
Treatment failure due to WRF, % (n) 28.6 (6) 34.2 (13) 0 (0) 0 (0) 0.001
Mortality and rehospitalization, % (n)
180-day all-cause Mortality 42.9 (9) 23.7 (9) 12.5 (2) 12 (3) 0.013
60-day all-cause Mortality 33.3 (7) 7.9 (3) 0 (0) 4 (1) 0.003
60-day Heart Failure Rehospitalization 0 (0) 13.2 (5) 25 (4) 20 (5) 0.040
60-day Rehospitalisation 14.3 (3) 28.9 (11) 37.5 (6) 24 (6) 0.486
Characteristics of the 4 groups; failure-worsening, failure-intermediate, no change and improving. Values are depicted as mean ± SD or median and interquartile range. COPD indicates
chronic obstructive pulmonary disease; NYHA, NewYorkHeart Association; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker andWRF,worsening renal function.
a Diuretic Response: kilogram weight loss on day 4 per 40 mg of Lasix through day 3.
235E.L. Vegter et al. / International Journal of Cardiology 224 (2016) 231–239[41], in consensus with our previous study in which we report on
the predictive value miR-652-3p for mortality in heart failure patients
[10].
We found miR-106a-5p to be negatively correlated to creatinine,
which suggests a potential role in renal function. In another study by
our group, we previously demonstrated that low levels of this miRNA
were related to patients with worsening of renal function and higher
levels of NGAL [42]. This is in conjunction with the presently found as-
sociation of this miRNA with creatinine in specifically those patients
with the least favorable in-hospital course.
The other significant negative correlations between miR-199a-3p
and PCT, miR-18a-5p and PCT, and miR-223-3p and GDF-15 all suggest
a potential relation with inflammatory processes, although specific
relations between these miRNAs and biomarkers have not been de-
scribed before. Similarly, no literature was found supporting the associ-
ation between let-7i-5p and triglycerides in the failure-intermediategroup, although involvement of the let-7 family in lipid metabolism
has been previously reported [43,44].
We hypothesize that not all potential associations between the
selected miRNAs and biomarkers were reflected by the results of the
performed correlation analyses. A clear shift was observed towards
more negative correlations between miRNAs and biomarkers in the
failure-worsening group at 48 h, but the clinically complex nature of
AHF in combination with the relatively low adjusted p-value threshold
might not allow for the statistical significant detection of all relevant
correlations at a given time pointwithin the limited number of patients.
MiRNAs fine tune cellular responses by regulating a large number of
targets in various pathological and physiological conditions. MiRNAs
can alter the expression of signalingmolecules within a particular path-
way and evidence accumulates that they could also act as modulators
between multiple pathways [45]. In addition to our attempt to use
known biomarkers to position the AHF-related miRNAs in relevant
Fig. 2. Correlation heatmaps. Heatmaps for the 4 clinical groups at 48 h of hospitalization. Red indicates a negative correlation, green a positive correlation. Increasing intensity of the color corresponds to a stronger correlation, the numbers in the
heatmap represent the Rho values. The significant correlations after correction are outlined in bold. A. Correlation heatmap of the improving group. B. Correlation heatmap of the no change group. C. Correlation heatmap of the failure-intermediate
group. D. Correlation heatmap of the failure-worsening group. CRP indicates C-reactive protein; TNFR-1, tumor necrosis factor alpha receptor 1; WAP-4C, WAP four-disulfide core domain protein HE4; sST-2, soluble ST-2; GDF-15, growth
differentiation factor 15; BUN, blood urea nitrogen; proADM, pro-adrenomedullin and VEGFR-1, vascular endothelial growth factor receptor 1. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
236
E.L.V
egter
etal./InternationalJournalofCardiology
224
(2016)
231–239
Fig. 3. Pathway analysis heatmap. Significant pathways predicted by DIANA-miRPath (v.2.0) are depicted on the X-axis and miRNAs on the Y-axis. The color code represents
the log(p-value), with the most significant predicted miRNA-pathway interactions in red. (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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followed by pathway analysis.
Target prediction identified FLT1 encoding for VEGFR-1 to be
targeted bymiR-30e-5p andmiR-106a-5p by 3 independent prediction
programs. In TarBase, FLT1 is listed as a immunoprecipitation (IP)
validated target of miR-106-5p [46]. VEGFA and VEGFC are IP validated
targets of miR-30e-5p, which are closely linked to VEGFR-1 [47–49]. As
reviewed recently, soluble FLT1 plays an anti-angiogenic role whereas
VEGF acts as pro-angiogenic factor in peripartum cardiomyopathy
(PPCM) [50]. Increased FLT1 results in declined VEGF levels, in which
miRNAs might play a regulatory role. Insufficient cardiac expression of
VEGF has been suggested to lead to endothelium dysfunction and
heart failure development due to impaired blood flow [51]. These
findings strengthen the validity of the detected correlation between
VEGFR-1 and miR-30e-5p. Although there is no evidence in heart dis-
ease that would support the detected correlation between miR-30e
and VEGFR-1 in the improving group, in a breast cancer study, the sup-
pression of another miR-30 family member, miR-30b, was associated
with overexpression of VEGF genes [52].
For the biomarkers sST-2 and albumin predicted to be targeted by
miR-199a-3p and miR-27a-3p respectively, no supportive evidence of
a functional interaction could be found in the current literature.
Target prediction via DIANA-micro T-CDS resulted in a list of predict-
ed genes based on complementary 3′ untranslated regions and coding
sequences of the mRNA. Pathway analysis on the predicted targets
using DIANA-miRPath (v.2.0) led to 47 significantly enriched KEGG
pathways (Supplementary Table 5). PI3K-Akt, ErbB, TGF-β and focal ad-
hesion signaling pathways aswell as the ubiquitinmediated proteolysis
ranked among the top 10 enriched pathways. All of these pathways are
described to play a role in the development of heart failure. The PI3K-
Akt pathway regulates cardiomyocyte size, survival, angiogenesis andinflammation in both physiological and pathological cardiac hypertro-
phy [53]. It has also been reported that Akt and mTOR contribute to an-
giogenesis by increasing the expression of VEGF and angiopoietin-2
[53]. TGF-β plays a central role in induction of fibrosis and also acceler-
ates production of extracellularmatrix (ECM) proteins [54]. Focal adhe-
sion signaling pathways have been described as contributing factors to
fibrosis and cardiomyocyte hypertrophy [55].
The identification of top ranking signaling pathways involved in
cardiac remodeling, angiogenesis and inflammation coincides with the
clustering of the biomarkers that were found to be significantly
associated with 7 of the 12 AHF-related miRNAs.
4.1. Study limitations
Although we have identified interesting correlations between bio-
markers and miRNAs in patients with AHF, factors such as time depen-
dent miRNA and biomarker expression and clinical status challenged
the approach to use known functions of biomarkers to mechanistically
position the AHF-related miRNAs. In this regard, concomitant diseases,
medication and volume status contribute to the complex phenotype of
the AHF population and may have an influence on circulating bio-
markers and miRNAs. The study is further limited by the small sample
size of the subgroups and the lack of comparable healthy control pa-
tients. More information about the relation of circulating miRNAs and
biomarkers might be found in chronic heart failure patients, resembling
a more stable condition than patients hospitalized for AHF. Further-
more, the biological function of miRNAs in the circulation remains elu-
sive and whether these miRNAs can exert regulative effects on
pathways involved in heart failure, needs further investigation. Since
heart failure is a heterogeneous syndrome mostly affecting patients
with several comorbidities, a certain overlap in underlyingmechanisms
238 E.L. Vegter et al. / International Journal of Cardiology 224 (2016) 231–239of other diseases is not uncommon and therefore the identified path-
ways may also be of importance in related comorbidities. Due to the ro-
bustness of the results from our previous study [10] and the herein
described associations with biomarkers previously related to heart fail-
ure, we are confident about the reported correlations and their involve-
ment in AHF. Nonetheless, we emphasize on the need to experimentally
validate our results, as these results can only be regarded as hypothesis
generating. Experimental studies in a controlled environment (e.g. cul-
tured cardiomyocytes) with overexpressed or knock-downmiRNAs are
more likely to yield pathway and disease-related data.
However, to our knowledge, this is the first study investigating the
relation of circulating miRNAs in patients with AHF with a large panel
of biomarkers, in contrast with most studies which are mostly limited
to (NT-pro)BNP and troponin.
5. Conclusions
We found several associations between miRNAs and other,
established and novel biomarkers corresponding to a worse prognosis
in AHF patients with an unfavorable in-hospital course, at 48 h of hospi-
talization. SeveralmiRNA-biomarker correlation pairswere identified in
these worsening heart failure patients which could be linked to predict-
ed targets and pathways related to cardiac disease, such as cardiac
remodeling/fibrosis, inflammation and angiogenesis.
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